Cite

    Marion Sassier et al.. “Renal insufficiency is the leading cause of double maintenance (bevacizumab and pemetrexed) discontinuation for toxicity to advanced non-small cell lung cancer in real world setting.” Lung cancer, vol. 89, no. 2, n.d., pp. 161–166. http://access.bl.uk/ark:/81055/vdc_100042113037.0x000041